The Milken Institute Future of Health Summit – “Is AI Just What the Doctor-or Patient-Ordered?” Panel Discussion
The Milken Institute Future of Health Summit (FHS) convened the best minds in the world to confront the most significant health challenges by matching human, financial, and scientific resources with the most innovative, inclusive, and impactful ideas. Watch now the Future of Health Summit and the panel titled “Is AI Just What the Doctor-or Patient-Ordered?” […]
Intelligent Technology Brings Companies To A New Moment Of Truth
“Algorithms have long been used to uncover correlations but now they are closing in on more human-like abilities such as common sense and the understanding of causation.” Paul R. Daugherty and H. James Wilson, discuss in this article the future of AI and refer to it as A New Moment of Truth. GNS causal AI […]
GNS Healthcare Featured in Harvard Business Review Article on AI in the Workplace
GNS Healthcare is featured in the July/August issue of the Harvard Business Review as part of the article “Collaborative Intelligence: Humans and AI are Joining Forces”, a discussion of new digital tools and how AI can complement and augment human capabilities rather than replace humans in the work force. Colin Hill, CEO and Co-Founder, comments on […]
GNS Healthcare to Present Results on Prediction of Disease Progression Using AI in NASH Patients at The International Liver Congress™
CAMBRIDGE, Mass.– April 13, 2018– GNS Healthcare (GNS), a leading precision medicine company, will present results from a recent study on Friday, April 13th at the International Liver Congress™ 2018 in Paris. The analysis focused on the progression of Nonalcoholic Steatohepatitis (NASH), a type of advanced liver disease. Specifically, the objective was to build predictive models […]
GNS Board Member Dr. Adrian Weller appointed as Programme Director for Artificial Intelligence at The Alan Turing Institute
Today, The Alan Turing Institute announced the appointment of Dr. Adrian Weller as Programme Director for Artificial Intelligence. The Institute, named in honor of Alan Turing and based in London, aims to make great leaps in data science research in order to change the world for the better. His role will enable the Institute to […]
Roche Precision Medicine Article Features Iya Khalil
Dr. Iya Khalil, GNS chief commercial officer and co-founder, gave her perspectives on the application of machine learning to clinical trials in “Partnering in the Digital Era“, an article published by Roche this week. The precision medicine piece focuses on how collaborations between healthcare and technology companies are driving the future of healthcare and features […]
Neo.Life features Iya Khalil in 2018 Biotech Breakthroughs and Big Ideas
In this January article, Neo.Life profiles the biggest biotech breakthroughs and big ideas for 2018, including thoughts from Iya Khalil, GNS co-founder and chief commercial officer. Iya speaks to the proliferation of emerging -omic data and how advances in artificial intelligence, and specifically causal machine learning, can use this data to drive better health outcomes […]
GNS Healthcare Uses Causal AI to Discover Which Multiple Myeloma Patients Will Have Progression Free Survival Benefit from Stem Cell Treatments
Details of the Discovery Leveraging the Multiple Myeloma Research Foundation CoMMpass Study Presented at 59th Annual ASH Meeting CAMBRIDGE, Mass.– December 12, 2017 – GNS Healthcare (GNS), a leading precision medicine company, together with the Multiple Myeloma Research Foundation (MMRF), have discovered a biomarker that identifies which multiple myeloma patients will benefit from stem cell transplantation. […]
Genentech oncology collaboration with GNS featured in TechEmergence
October 11, 2017 by Jon Walker Genentech, a member of the Roche Group, this summer announced their own collaboration with Cambridge, MA-based GNS Healthcare. GNS Healthcare’s mission statement is to use the latest innovations in machine learning to turn biomedical data into solutions and treatments. This collaboration’s first focus will also be on oncology, just like the IBM/Pfizer deal. Genentech […]
FierceBiotech features Alexion-GNS Partnership Targeting Rare Diseases
Alexion inks genomics pacts to continue R&D reboot August 11, 2017 – Alexion has teamed up with GNS Healthcare and Sema4 to advance its rare disease R&D agenda. The partnerships give Alexion access to modeling and simulation software used by Celgene and a partner to support its push into genomics. Read the full article here. […]